What Meribel Pharma Solutions does

Meribel Pharma Solutions is a UK-headquartered, mid-size European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) that was formed in 2024 through the merger of Synerlab Group and seven manufacturing sites formerly operated by Recipharm, and officially launched commercial operations in April 2025. The company operates an integrated network of 13 manufacturing facilities — six in France, two in Spain, and five in Sweden — with more than 2,000 full-time employees across five countries, and is backed by Blue Wolf Capital Partners, a US middle-market private equity firm focused on industrial and healthcare sectors.

The company offers end-to-end CDMO services spanning formulation development, analytical development, process development, commercial-scale manufacturing, packaging, regulatory affairs, technology transfer, and specials (unlicensed medicines). It manufactures across five principal dosage forms — oral solids, liquids, semi-solids, steriles, and sachets/stick packs — with particular domain specialisation in sterile multidoses (drawing on over three decades of legacy expertise), lyophilisation (including cryogenic and API lyophilisation), and sachets/stick packs. Multiple sites hold cGMP (EU), FDA, and PMDA (Japan) certifications, along with ISO 13485, 14001, and 45001 credentials at Swedish sites, enabling the company to serve pharmaceutical clients across major regulated markets.

Meribel operates a B2B contract-services revenue model, generating revenue through long-term commercial supply and development contracts with pharmaceutical companies — including generic drug manufacturers, innovative pharma, and biotechs — at negotiated per-project pricing. The go-to-market is enterprise sales-led, supported by a Chief Commercial Officer, dedicated commercial teams, and active presence at industry events such as CPHI Frankfurt (October 2025) and CDMO Live Rotterdam (May 2026, Gold Partner). The company has stated an ambition to double revenue within five years under Blue Wolf Capital's ownership.

Name

Meribel Pharma Solutions

Legal name

BW CDMO Topco Uk Limited

Website

https://meribelpharma.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Meribel Pharma Solutions is a UK-headquartered mid-size European CDMO operating 13 manufacturing sites across France, Spain, and Sweden with 2,000+ staff, offering end-to-end pharmaceutical development, manufacturing, and packaging services — with specialisations in sterile multidoses, lyophilisation, and sachets/stick packs — to pharmaceutical and biotech clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule API & Intermediates CDMO (HLAGABAA), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

Keywords

• Contract pharmaceutical manufacturing
• Lyophilisation services
• Sterile manufacturing
• Oral solid dose
• Pharmaceutical development services

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices13 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: As a CDMO, Meribel Pharma Solutions generates revenue through providing end-to-end pharmaceutical development and manufacturing services to pharmaceutical companies. Services include formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer. Revenue is generated through long-term contracts with pharmaceutical companies for product development and commercial manufacturing.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Meribel Pharma Solutions is a mid-size European Contract Development and Manufacturing Organisation (CDMO) providing end-to-end pharmaceutical services from concept through commercialisation. The company delivers formulation development, analytical development, process development, manufacturing, packaging, regulatory affairs, and technology transfer across 13 manufacturing sites in France, Spain, and Sweden. Core specialisations include lyophilisation (including API and cryogenic), sterile multidose manufacturing with terminal sterilisation, sachets and stick packs, oral solid dose production, semi-solids, and sterile non-injectable liquids for pharmaceutical company clients.

Product overview

Meribel Pharma Solutions is a mid-size, full-service Contract Development and Manufacturing Organisation (CDMO) offering an integrated network of pharmaceutical development and manufacturing services across Europe. The company's product portfolio includes three core service areas: Development Services (comprising Formulation Development, Analytical Development, and Process Development), Manufacturing Services for multiple dosage forms, and Regulatory Affairs. The company specialises in five key dosage forms: Oral Solids, Liquids, Semi-Solids, Steriles, and Sachets/Stick Packs. The service offering is built around particular specialisations in sterile multidoses, sterile and non-sterile lyophilised products, API lyophilisation, sachets and stick packs. Additional services include Packaging, Technology Transfer, Specials, and Quality assurance. The integrated network across 13 sites in France, Spain, and Sweden enables seamless support from concept through to commercialisation.

Differentiator

Problem solved

Functional benefit

Products and services

• Lyophilisation Services Flexible and responsive lyophilisation (freeze-drying) services across the entire value chain, with particular specialisation in API lyophilisation and cryogenic/extreme cold processing capabilities. Sold to pharmaceutical companies requiring contract lyophilisation manufacturing.
• Sterile Multidose Services Expert sterile multidose development and manufacturing services with over three decades of experience, including sterile and non-sterile lyophilised products, terminal sterilisation, and WFI (Water for Injection) production. Sold to pharmaceutical companies.
• Development Services Comprehensive drug development services including formulation development, analytical development, and process development for pharmaceutical clients. Sold as an integrated development service to pharmaceutical companies.
• Manufacturing Services Diverse manufacturing technologies and experienced team ensuring high-quality and efficient production of drug products across multiple dosage forms. Sold as contract manufacturing to pharmaceutical companies.
• Packaging Services Pharmaceutical packaging solutions grounded in knowledge and insight, including large-scale sachet and stick pack packaging capacity. Sold as contract packaging services to pharmaceutical companies.
• Regulatory Affairs Services Regulatory affairs services in the EU to help navigate the complexities of global pharmaceutical regulations for medicinal products. Sold to pharmaceutical companies requiring multi-jurisdictional regulatory support.
• Technology Transfer Services Flexible approach to technology transfer that adapts to unique customer requirements and timelines, enabling seamless movement of products and processes between sites. Sold to pharmaceutical companies requiring tech transfer support.
• Specials Services Solutions for complex pharmaceutical challenges where standard approaches may not apply. Sold to pharmaceutical companies requiring tailored manufacturing solutions for complex products.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Almac Group: UK/Northern Ireland-headquartered CDMO with comparable pharmaceutical development, manufacturing, and clinical services. Competes for similar European pharma contracts at greater scale and broader service breadth.
• Lonza: Swiss-headquartered global CDMO leader across small molecules, biologics, and cell/gene therapy. Operates at much larger scale than Meribel but competes for the same European pharma outsourcing wallet, particularly for sterile and complex dosage forms.
• Catalent: Global large-molecule and small-molecule CDMO with comparable service lines (oral solids, sterile, softgel, biologics). Competes with Meribel for mid-tier pharma contracts but at much greater scale and with broader dosage-form breadth.

Direct peers

• Euroapi: European API and intermediates CDMO spun off from Sanofi in 2022. Comparable regulatory heritage, French-headquartered, and competing for the same European pharma outsourcing customers, particularly on API and complex synthesis.
• Delpharm: French-headquartered CDMO specialising in sterile and non-sterile pharmaceutical manufacturing, particularly oral solids and injectables. Directly comparable European mid-size CDMO competing for the same generic and innovative-pharma customers as Meribel.
• Fareva: France-based contract manufacturer with pharmaceutical (CDMO), cosmetic, and industrial operations. Comparable pharmaceutical manufacturing scale and European footprint, especially in France, competing in similar dosage forms.
• Hovione: Portugal-headquartered CDMO specialising in API development and manufacturing, inhalation, and oral dosage forms. Comparable as a European specialist CDMO serving global pharma with similar regulatory certifications.
• Recipharm: European CDMO focused on small-molecule drug product manufacturing across sterile, semi-solid, and oral solid dosage forms — directly comparable to Meribel across both service offering and target pharma customer base. Seven of Meribel's sites were carved out from Recipharm in 2024.
• CordenPharma: European CDMO providing API manufacturing (peptides, lipids, carbohydrates) and drug product services across sterile and oral dosage forms. Comparable as a mid-to-large European CDMO platform serving global pharma customers.
• Aenova: European mid-size CDMO with similar portfolio across solid, semi-solid, liquid, and sterile dosage forms. Comparable in scale and footprint, competing head-to-head for mid-size pharma contract manufacturing business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/meribel-pharma-solutions

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Meribel Pharma Solutions